Source link : https://newshealth.biz/health-news/fda-drops-rems-programs-for-some-car-ts/
Using chimeric antigen receptor (CAR) T-cell therapies for blood cancer should be less burdensome following labeling updates from the FDA. Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel (Carvykti; Janssen) and idecabtagene vicleucel (Abecma; BMS) — and one […]
The post FDA Drops REMS Programs for Some CAR-Ts first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-30 16:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8